The Rosewood study shows the combination of zanubrutinib and obinutuzumab is highly effective in high-risk, relapsed/refractory follicular lymphoma. This is a significant finding because BTK inhibitors as a class have historically shown minimal activity in this disease, suggesting this specific combination creates a new therapeutic opportunity.
The phase 3 INMIND trial showed adding tofacitimab to lenalidomide and rituximab (R-squared) significantly improves progression-free survival over R-squared alone. This fixed-duration regimen with a manageable toxicity profile is now considered a new standard of care for this patient population, including high-risk subsets.
A key clinical concern with CD19-directed therapies is antigen loss, which could prevent future CAR T-cell treatments. Data from the INMIND trial alleviates this fear, showing that 23 of 24 post-treatment lymphoma samples retained CD19 expression, suggesting tofacitimab does not preclude subsequent CAR-T therapy.
The ECHO trial's long-term follow-up demonstrates that adding acalabrutinib to BR chemotherapy in frontline MCL not only improves progression-free survival but also drastically reduces the need for subsequent therapy. This challenges the common clinical practice of reserving potent BTK inhibitors for later lines of treatment.
Clinical trials often mandate indefinite acalabrutinib treatment until progression. However, emerging data suggests Minimal Residual Disease (MRD) status could serve as a biomarker to guide de-escalation. Achieving MRD negativity may allow physicians to safely stop the BTK inhibitor, personalizing treatment duration to reduce toxicity and cost.
The traditional approach of stratifying Mantle Cell Lymphoma patients as "younger/fit" or "older/unfit" is becoming obsolete. As effective targeted therapies reduce reliance on intensive chemo and transplant, biologic markers like P53 status and KI-67 proliferation index are becoming the primary drivers of risk assessment and treatment selection.